Identifier to cite or link to this item: http://hdl.handle.net/20.500.13003/11409
Extracellular vesicle-miRNAs as liquid biopsy biomarkers for disease identification and prognosis in metastatic colorectal cancer patients
Identifiers
ISSN: 2045-2322
WOS ID: 000563271000005
Scopus EID: 2-s2.0-85081239048
PMID: 32132553
Embase PUI: L631165088
Share
Statistics
Item usage statisticsMetadata
Show Dublin Core item recordPublication date
2020-03-04Document type
research articleCitation
De Miguel Perez D, Rodriguez Martinez A, Ortigosa Palomo A, Delgado Urena M, Garcia Puche JL, Robles Remacho A, et al. Extracellular vesicle-miRNAs as liquid biopsy biomarkers for disease identification and prognosis in metastatic colorectal cancer patients. Sci Rep. 2020 Mar 04;10(1):3974.Abstract
Disseminated disease is present in approximate to 50% of colorectal cancer patients upon diagnosis, being responsible for most of cancer deaths. Addition of biological drugs, as Bevacizumab, to chemotherapy, has increased progression free survival and overall survival of metastatic colorectal cancer (mCRC) patients. However, these benefits have been only reported in a small proportion of patients. To date, there are not biomarkers that could explain the heterogeneity of this disease and would help in treatment selection. Recent findings demonstrated that microRNAs (miRNAs) play an important role in cancer and they can be encapsulated with high stability into extracellular vesicles (EVs) that are released in biological fluids. EVs can act as cell-to-cell communicators, transferring genetic information, such as miRNAs. In this context, we aimed to investigate serum EV associated miRNAs (EV-miRNAs) as novel non-invasive biomarkers for the diagnosis and prognosis of Bevacizumab-treated mCRC patients. We observed that baseline miRNA-21 and 92a outperformed carcinoembryonic antigen levels in the diagnosis of our 44 mCRC patients, compared to 17 healthy volunteers. In addition, patients who died presented higher levels of miRNA-92a and 222 at 24 weeks. However, in the multivariate Cox analysis, higher levels of miRNA-222 at 24 weeks were associated with lower overall survival. Altogether, these data indicate that EV-miRNAs have a strong potential as liquid biopsy biomarkers for the identification and prognosis of mCRC.
Publisher version
https://dx.doi.org/10.1038/s41598-020-60212-1MeSH
Disease-Free SurvivalMale
MicroRNAs
Neoplasm Metastasis
Biomarkers, Tumor
Female
Extracellular Vesicles
Colorectal Neoplasms
Humans
Middle Aged
DeCS
Neoplasias ColorrectalesHumanos
Persona de Mediana Edad
Vesículas Extracelulares
Femenino
Biomarcadores de Tumor
Metástasis de la Neoplasia
Supervivencia sin Enfermedad
Masculino
MicroARNs